Shift Toward Macrocyclic & Non-Ionic Agents
Following a series of regulatory bans by the Ministry of Food and Drug Safety (MFDS) on high-risk linear agents, the 2026 market is dominated by safer, "Macrocyclic" formulations.
MRI Standards: Linear gadolinium-based agents (GBCAs) have been largely phased out in favor of macrocyclic alternatives like Pixxoscan (gadobutrol) and Clariscan. These agents are preferred because they do not "leak" gadolinium ions into brain or bone tissue, a key concern for Korea's long-term patient safety protocols.
CT Innovation: For X-ray and CT, Non-ionic, Low-Osmolar Contrast Media (LOCM) has become the absolute baseline. These formulations are specifically designed to be "kidney-friendly," catering to South Korea's growing elderly demographic who often suffer from reduced renal function.
Hypersensitivity Registry: In 2026, the MFDS has established a national registry for hypersensitivity reactions, allowing for the first real-time, nation-wide tracking of adverse events related to specific contrast media brands.